EVALUATE AND COMPARE INCIDENCE OF CARDIOMYOPATHY ASSOCIATED WITH TRASTUZUMAB, PERTUZUMAB, LAPATINIB, NERATINIB, AND TDM-1 USED IN TREATMENT OF HER-2 POSITIVE BREAST CANCER

Human Epidermal Growth Factor Receptor- 2 (HER-2) positive breast cancer represents about 15-20% of invasive breast carcinoma. Monoclonal antibodies such as Trastuzumab and pertuzumab along with newer targeted agents such as Lapatinib, neratinib and TDM-1 are used for its treatment. Trastuzumab has